Skip to Main Content

Paper Details

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Cancer Cell
247
2014
-, -ABL1 allele, ABL1, BCR, Ph, Ph chromosome, Ph chromosome-positive leukemia, Ph(+) leukemia, Philadelphia, Philadelphia chromosome-positive (Ph(+), Ponatinib, T315I, bosutinib, dasatinib, imatinib, nilotinib, patients, ponatinib, rebastinib, tyrosine, tyrosine kinase
Author NameAffiliation
Matthew S ZabriskieHuntsman Cancer Institute, University of Utah
Christopher A EideOregon Health & Science University Knight Cancer Institute, USA Howard Hughes Medical Institute
Srinivas K TantravahiHuntsman Cancer Institute, University of Utah
Jorge CortesUniversity of Texas MD Anderson Cancer Center
Hagop KantarjianUniversity of Texas MD Anderson Cancer Center
Steven M KornblauUniversity of Texas MD Anderson Cancer Center
Thoralf LangeUniversity of Leipzig
Richard D PressDepartment of Pathology and Knight Cancer Institute, Oregon Health & Science University
Anna M EiringHuntsman Cancer Institute, University of Utah
Anthony D PomicterHuntsman Cancer Institute, University of Utah
Jamshid S KhorashadHuntsman Cancer Institute, University of Utah
Riccardo BaronUniversity of Utah
Brian J DrukerOregon Health & Science University Knight Cancer Institute, USA Howard Hughes Medical Institute
Michael W DeiningerHuntsman Cancer Institute, University of Utah
Thomas O'HareHuntsman Cancer Institute, University of Utah
  • 1 - 15

Datasets